EUVIMEDOtkrijte EUVIMED
Open access · CC BY-NC 4.0

Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant

Mohammed Alzahrani, Rachel M Belcher iD, Jamie Benken iD, Benito Valdepenas, Pierpaolo Di Cocco, Mathula Kajavathanan, Scott T Benken iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15082 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Mohammed Alzahrani and 6 co-authors. Institution: Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA. Major MEDLINE topics: Tacrolimus, Kidney Transplantation. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Veloxis Pharmaceuticals.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Introduction

Tacrolimus is known to exhibit significant inter‐ and intra‐patient pharmacokinetic (PK) and pharmacodynamic (PD) variability regarding therapeutic response. LCP‐tacrolimus (LCPT—Envarsus XR) was approved in 2018 for use as a de novo immunosuppressive agent in kidney transplants, but there is limited evidence to guide de novo dosing of LCPT in patients with obesity. The primary objective of this study was to evaluate the impact of different calculated weight‐based de novo LCPT dosing on early transplant outcomes.

Methods

This was a retrospective study of patients with obesity (BMI ≥ 30 kg/m 2 ) who received a kidney transplant at the University of Illinois Hospital and Health System (UIH), between March 2019 and March 2021. Subjects were included if were age 18 years or older and received de novo LCPT throughout index hospitalization. The primary endpoint of this study was to compare correlations between the first tacrolimus trough level and dosing weight strategy (e.g., TBW, AdjBW, IBW).

Results

There was a statistically significant, though modest, correlation between all three dosing strategies and the first tacrolimus trough level (TBW correlation coefficient = .431, p < .001; AdjBW correlation coefficient = .455, p < .001; IBW correlation coefficient = .465; p < .001). In regression modeling for supratherapeutic levels each additional .01 mg/kg increase in dose by TBW, AdjBW, and IBW increased the odds of a supratherapeutic level by 1.46, 1.34, and 1.24, respectively ( p < .001).

Conclusions

The use of LCPT in kidney transplant recipients with obesity dosed using TBW demonstrated the strongest correlation with initial supratherapeutic tacrolimus levels. Larger prospective studies are needed to investigate the further impact of body weight on dosing regimens in the obese population.

Subjects

MeSH terms (MEDLINE)

TacrolimusKidney TransplantationHumansAdolescentRetrospective StudiesDrug Administration ScheduleImmunosuppressive AgentsObesity

Author keywords

kidney transplantobesityrenaltacrolimustransplantation

Substances

TacrolimusImmunosuppressive Agents

Authors and institutions

  • Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

ORCID profiles: Rachel M Belcher, Jamie Benken, Scott T Benken

Funding

  • Veloxis Pharmaceuticals

Cite

APA

Alzahrani, M., Belcher, R. M., Benken, J., Valdepenas, B., Di Cocco, P., Kajavathanan, M., & Benken, S. T. (2023). Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.15082

Vancouver

Alzahrani M, Belcher RM, Benken J, Valdepenas B, Di Cocco P, Kajavathanan M, et al. Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. 2023. doi:10.1111/ctr.15082

BibTeX
@article{Alzahrani2023,
  author = {Alzahrani, Mohammed and Belcher, Rachel M and Benken, Jamie and Valdepenas, Benito and Di Cocco, Pierpaolo and Kajavathanan, Mathula and Benken, Scott T},
  title = {Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15082}
}
Start for free →